MRI- and PET-based imaging markers for the diagnosis of Alzheimer's disease

Stefan Teipel, Reisa A. Sperling, Pawel Skudlarski, Clifford Jack, Harald Hampel, Andreas Fellgiebel, Karl Herholz

    Research output: Chapter in Book/Report/Conference proceedingChapter


    Imaging markers of early neurodegeneration play an important role for the definition of predementia and preclinical stages of Alzheimer's disease according to the newly proposed diagnostic consensus criteria. Markers of regional and global brain atrophy in MRI and the detection of cortical metabolic decline and cerebral amyloid deposition using PET are the best established imaging markers for prodromal and clinical Alzheimer's disease to date. Detection of structural and functional cortical disconnection using functional MRI and diffusion tensor imaging add to the diagnostic sensitivity and specificity. Important areas of future research are the application of imaging markers in large multicenter studies, and their implementation in radiological expert systems for diagnosis. Additionally, we need to consider the effect of these new markers on care for patients and counseling of at-risk subjects. Copyright © 2012 S. Karger AG, Basel.
    Original languageEnglish
    Title of host publicationAdvances in Biological Psychiatry|Adv. Biol. Psychiatry
    Place of PublicationBasel
    PublisherS. Karger AG
    Number of pages34
    Publication statusPublished - 2012

    Publication series

    NameAdv Biol Psychiatry, Vol 28


    Dive into the research topics of 'MRI- and PET-based imaging markers for the diagnosis of Alzheimer's disease'. Together they form a unique fingerprint.

    Cite this